Cell Banking Strategy

Cell banking strategy encompasses the establishment, qualification, and maintenance of master and working cell banks supporting consistent biopharmaceutical manufacturing. Banking systems employ cryopreservation techniques stabilising viable cell populations across production campaigns, ensuring genetic and phenotypic stability from generation to generation. Master cell bank development requires extensive characterisation including viability, sterility, mycoplasma testing, adventitious agent screening, and genetic stability assessment through passage limitation studies. Working cell banks derived from master banks undergo accelerated stability protocols validating consistency and potency across manufacturing runs.

Continuous cell line banking addresses immortalised and primary cell populations requiring extended propagation. Regulatory guidelines establish maximum passage numbers balancing manufacturing convenience against genetic drift risk. Cryopreservation formulations incorporating glycerol, dimethyl sulphoxide, and cryoprotectants optimise post-thaw recovery rates. Advanced banking strategies employ multiple independent clones reducing dependency on single cell lines and enabling parallel process development. Quality systems tracking banking history, thaw records, and passage genealogy support regulatory compliance and manufacturing traceability throughout product lifecycle.